en · de · es
semax-notes.peptides3626.com › Faq › Semax Background And Chemistry — Reference Sheet

Semax Background And Chemistry — Reference Sheet

By Editorial Desk · published 2025-12-17 · last reviewed 2026-01-07 · Faq

Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-01-07. Numbers and descriptions here follow the published literature rather than marketing material.

Semax Background and Chemistry

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.

Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Background and Development

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SContains one methionine sulfur atom
Molecular massApproximately 814 DaConsistent with a seven-residue peptide
AppearanceWhite to off-white powderTypical lyophilized form
SolubilityFreely soluble in waterAlso soluble in dimethyl sulfoxide
Typical storage-20 °C, desiccatedLimits methionine oxidation

Background and Development History

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Related pages on this site

Background from the literature

== Divisions == Roche has two major divisions: Pharmaceuticals and Diagnostics. Roche Diagnostics manufactures diagnostic equipment and reagents for research and medical diagnostic applications. Internally, it is organised into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana). The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland. All business areas except Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers. Applied Science targets research settings in academia and pharmaceutical and biotechnology industries.

=== mzML === Owing to the undesirability of having two formats (namely mzData and mzXML) representing the same information, a joint effort was set up by HUPO-PSI, the SPC/ISB, and instruments vendors to create a unified standard, borrowing the best aspects of both mzData and mzXML and intending to replace both. Originally called dataXML, it was officially announced as mzML. The first specification was published in June 2008. This format was officially released at the 2008 American Society for Mass Spectrometry Meeting, and has since then been relatively stable, having received very few updates. On 1 June 2009, mzML 1.1.0 was released. There were no further changes planned as of 2013.

=== Uterine effects === Under normal physiological circumstances, progesterone secreted by the corpus luteum during the luteal phase of the menstrual cycle produces endometrial transformation of the estrogen-primed uterus in preparation for implantation and pregnancy. Normal progesterone production during the luteal phase is 25 mg/day on average with a range of 15 to 50 mg/day. Progesterone levels during the luteal phase range from 7 ng/mL to 22 ng/mL using liquid chromatography–tandem mass spectrometry (LC–MS/MS) per one source. Sustained progesterone levels of more than 5 ng/mL, perhaps approximately 10 ng/mL, are required for full endometrial transformation. Progesterone levels of more than 10 ng/mL are rarely associated with luteal-phase defect on the basis of endometrial biopsy. Luteal-phase levels of progesterone are said to be produced by 25 mg/day progesterone in oil solution by intramuscular injection or by 100 mg/day progesterone by vaginal or rectal administration. Progesterone by intramuscular injection in oil solution has been found to produce endometrial transformation at a dose of 10 or 20 mg/day for 14 days (total dose per cycle of 200 mg), whereas a single intramuscular injection of 200 mg progesterone in microcrystalline aqueous suspension provides endometrial transformation after 10 to 14 days. A study found full and equivalent endometrial transformation with subcutaneous injection of 25 mg/day versus 50 mg/day progesterone in aqueous solution.

Hemoglobin has a quaternary structure characteristic of many multi-subunit globular proteins. Most of the amino acids in hemoglobin form alpha helices, and these helices are connected by short non-helical segments. Hydrogen bonds stabilize the helical sections inside this protein, causing attractions within the molecule, which then causes each polypeptide chain to fold into a specific shape. Hemoglobin's quaternary structure comes from its four subunits in roughly a tetrahedral arrangement. In most vertebrates, the hemoglobin molecule is an assembly of four globular protein subunits. Each subunit is composed of a protein chain tightly associated with a non-protein prosthetic heme group. Each protein chain arranges into a set of alpha-helix structural segments connected together in a globin fold arrangement. Such a name is given because this arrangement is the same folding motif used in other heme/globin proteins such as myoglobin. This folding pattern contains a pocket that strongly binds the heme group. A heme group consists of an iron (Fe) ion held in a heterocyclic ring, known as a porphyrin. This porphyrin ring consists of four pyrrole molecules cyclically linked together (by methine bridges) with the iron ion bound in the center. The iron ion, which is the site of oxygen binding, coordinates with the four nitrogen atoms in the center of the ring, which all lie in one plane. The heme is bound strongly (covalently) to the globular protein via the N atoms of the imidazole ring of F8 histidine residue (also known as the proximal histidine) below the porphyrin ring.

Sources: en.wikipedia.org

Further detail

== Mechanical properties == Implementing MOFs in industry necessitates a thorough understanding of the mechanical properties since most processing techniques (e.g., extrusion and pelletization) expose the MOFs to substantial mechanical compressive stresses. The mechanical response of porous structures is of interest as these structures can exhibit unusual response to high pressures. While zeolites (microporous, aluminosilicate minerals) can give some insights into the mechanical response of MOFs, the presence of organic linkers as opposed to zeolites, makes for novel mechanical responses. MOFs are structurally diverse meaning that it is challenging to classify all of their mechanical properties. Additionally, variability in MOFs from batch to batch and extreme experimental conditions (diamond anvil cells) mean that experimental determination of mechanical response to loading is limited, however many computational models have been made to determine structure-property relationships. Main MOF systems that have been explored are zeolitic imidazolate frameworks (ZIFs), Carboxylate MOFs, Zirconium-based MOFs, among others. Generally, the MOFs undergo three processes under compressive loading (which is relevant in a processing context): amorphization, hyperfilling, and/or pressure induced phase transitions. During amorphization linkers buckle and the internal porosity within the MOF collapses. During hyperfilling the MOF which is being hydrostatically compressed in a liquid (typically solvent) will expand rather than contract due to a filling of pores with the loading media.

Construction was interrupted by Cuba's involvement in World War I, but it was completed on February 9, 1920. On opening day, hundreds of visitors from around Havana and the surrounding areas came to tour the facility, including the Provincial Governor of Havana, Colonel Alberto Barreras, who was also a Freemason. Governor Barrearas oversaw a twelve gun salute and a performance of La Bayamesa by the General Staff Band. Three flags were raised; the flag of Cuba, the flag of the Supreme Council of Cuba, and the flag of the Grand Lodge of Cuba. Priority was given to Freemasons, but anyone could apply for housing here. There were only four rules needed to become a resident here: Residents had to be someone who needed public charity to live, "...even if they got there through vices." Residents had to be homeless. If the resident wasn't a Freemason, they needed to have letters of recommendation. All residents needed to pay up to 100 dollars to secure housing. As the years went by, the name "Asilo," or Asylum, became increasingly problematic. The original business model of the Mercy Asylum under its previous owners from 1886 had been to take beggars off of the street and put them into the shelter. As Cuba's new sphere of academia and the social welfare science studies advanced, earlier common practices in charity and relief work were radically transformed. Around the world, people began associating the term asylum with places like Bellevue Hospital and Bethlem Royal Hospital, and the Freemasons wanted to avoid that association.

=== Greece === In Greece, licensed physicians are eligible to apply for a position in a residency program. To be a licensed physician, one must finish a medical training program which in Greece lasts for six years. A one-year obligatory rural medical service (internship) is necessary to complete the residency training. Applications are made individually in the prefecture where the hospital is located, and the applicants are positioned on first-come, first-served basis. The duration of the residency programs varies between three and seven years.

=== Simplifying Peptide Synthesis === CITU—reagent for peptide synthesis and decarboxylative cross-coupling (2017) Thermodynamic peptide macrocyclization (2017) General method for chemoselective, and modular functionalization of serine residues (2020)

Electrospun nanofibers are useful for removing volatile organic compounds (VOC) from the atmosphere. Scholten et al. showed that adsorption and desorption of VOC by electrospun nanofibrous membrane were faster than the rates of conventional activated carbon. Airborne contamination in the personnel cabins of mining equipment is of concern to the mining workers, mining companies, and government agencies such as the Mine Safety and Health Administration (MSHA). Recent work with mining equipment manufacturers and the MSHA has shown that nanofiber filter media can reduce cabin dust concentration to a greater extent compared to standard cellulose filter media. Nanofibers can be used in masks to protect people from viruses, bacteria, smog, dust, allergens and other particles. Filtration efficiency is at about 99.9% and the principle of filtration is mechanical. Particles in the air are bigger than pores in nanofiber web, but oxygen particles are small enough to pass through.

Sources: en.wikipedia.org

Frequently asked questions

Is semax an approved medicine?

It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.

How is semax usually given in studies?

Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.

What does a purity figure actually tell a buyer?

A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.

Where was Semax developed?

It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.

Network